Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax plus zanubrutinib for treatment-naïve Waldenström macroglobulinemia
ChiCTR2600129561Phase 4Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Aug 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sonrotoclax and zanubrutinib in Waldenström macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Proportion of VGPR or CR within 24 cycles. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
sonrotoclaxzanubrutinib
03
Conditions
Waldenström macroglobulinemia (WM)Lymphoplasmacytic Lymphoma (LPL)
Beyond the preview
Go deeper on ChiCTR2600129561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129561.